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Abstract
Purpose We have previously described a novel pathway
controlling drug resistance, epithelial-to-mesenchymal
transition (EMT) and stemness in breast cancer cells.
Upstream in the pathway, three miRs (miR-106b, miR-93
and miR-25) target EP300, a transcriptional activator of
E-cadherin. Upregulation of these miRs leads to the
downregulation of EP300 and E-cadherin with initiation of
an EMT. However, miRs regulate the expression of many
genes, and the contribution to EMT by miR targets other
than EP300 cannot be ruled out.
Methods We used lentiviruses expressing EP300-targeting
shRNA to downregulate its expression in MCF-7 cells as
well as an EP300-knocked-out colon carcinoma cell line.
An EP300-expression plasmid was used to upregulate its
expression in basal-like CAL51 and MDA-MB-231 breast
cancer cells. Drug resistance was determined by short-term
proliferation and long-term colony formation assays.
Stemness was determined by tumour sphere formation in
both soft agar and liquid cultures as well as by the
expression of CD44/CD24/ALDH markers. Gene expres-
sion microarray analysis was performed in MCF-7 cells
lacking EP300. EP300 expression was analysed by
immunohistochemistry in 17 samples of metaplastic breast
cancer.
Results Cells lacking EP300 became more resistant to
paclitaxel whereas EP300 overexpression increased their
sensitivity to the drug. Expression of cancer stem cell
markers, as well as tumour sphere formation, was also
increased in EP300-depleted cells, and was diminished in
EP300-overexpressing cells. The EP300-regulated gene
signature highlighted genes associated with adhesion
(CEACAM5), cytoskeletal remodelling (CAPN9), stemness
(ABCG2), apoptosis (BCL2) and metastasis (TGFB2).
Some genes in this signature were also validated in a
previously generated EP300-depleted model of breast
cancer using minimally transformed mammary epithelialElectronic supplementary material The online version of this
article (doi:10.1007/s10549-017-4202-z) contains supplementary
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cells. Importantly, two key genes in apoptosis and stem-
ness, BCL2 and ABCG2, were also upregulated in EP300-
knockout colon carcinoma cells and their paclitaxel-resis-
tant derivatives. Immunohistochemical analysis demon-
strated that EP300 expression was low in metaplastic breast
cancer, a rare, but aggressive form of the disease with poor
prognosis that is characterized by morphological and
physiological features of EMT.
Conclusions EP300 plays a major role in the reprogram-
ming events, leading to a more malignant phenotype with
the acquisition of drug resistance and cell plasticity, a
characteristic of metaplastic breast cancer.
Keywords Metastasis  Cancer stem cells  Drug
resistance  BCL2  ABCG2  EP300 signature
Abbreviations
ALDH Aldehyde dehydrogenase
CSC Cancer stem cell
DMEM Dulbecco’s modified Eagle medium
EMT Epithelial-to-mesenchymal transition
IC50 Drug concentration producing 50% cell death
miR Micro RNA




Many breast cancers initially respond well to chemotherapy,
however, in a significant proportion of cases, and following a
cancer-free period, metastases at distant sites appear and
these are accompanied by a poor response to therapy, nor-
mally with fatal consequences. It is thus imperative to
improve our understanding of the mechanisms leading to
cancer spread and therapy response with the aim of devel-
oping new markers and therapeutic strategies [1].
Epithelial cells undergoing epithelial-to-mesenchymal
transition (EMT, the first step in the metastatic cascade)
lose E-cadherin expression and their characteristic epithe-
lial morphology. These events are accompanied by an
increase in motility and acquisition of the ability to degrade
the extracellular matrix and invade other tissues. Loss of
E-cadherin, a hallmark of the EMT programme, liberates
b-catenin (normally associated with the C-terminus of
E-cadherin), which migrates to the nucleus and induces the
expression of genes orchestrating the EMT programme.
Importantly, the EMT programme generates cancer cells
with stem cell-like characteristics (cancer stem cells,
CSCs). EMT and CSCs are often associated with the
acquisition of drug resistance. Thus, these three processes
are tightly interlinked [2–4].
Downregulation of E-cadherin by transcriptional
repressors (Snail and Slug, as well as ZEB1, ZEB2 and
Twist) is well-studied. However, transcriptional activators
of E-cadherin, which help maintain the cell in an epithelial
state, such as EP300, FOXA1 and RUNX1, are less well
characterized [5]. EP300 was originally discovered as a
transcriptional co-activator that plays pivotal roles in
integrating and mediating multiple signal-dependant tran-
scription events [6]. The most studied function of EP300 is
as a histone acetyltransferase, regulating transcription via
chromatin remodelling [7], and it has important roles in
cell proliferation, transformation and differentiation [8].
Loss of EP300 heterozygosity has been described in breast
carcinomas [9], somatic EP300 mutations have been
identified in several malignancies [10] and EP300-deficient
colon carcinoma cells show phenotypic changes charac-
teristic of EMT [11].
We have recently described a novel EMT/CSC/drug
resistance regulatory axis controlled by the miR-106b*25
cluster [12], which is associated with aggressive basal-like,
oestrogen receptor-negative, grade 3 breast cancers [13].
The three miRs in the cluster target EP300 mRNA and
downregulate its expression, leading to increased motility
and invasive properties as well as the generation of dox-
orubicin and radiation-resistant derivatives [12]. In bladder
cancer cells, experimental downregulation of EP300 also
leads to doxorubicin and cisplatin resistance [14], [15].
Using a minimally transformed mammary epithelial cell
model [16], we have also demonstrated that cells in which
this pathway has been experimentally downregulated
acquire a multidrug resistance phenotype with evasion
from apoptosis [17].
Here we show that experimental modulation of EP300
alters paclitaxel sensitivity and the generation of paclitaxel
resistance. EP300 silencing is also associated with
increased in vitro tumorigenicity and CSC-like markers,
whilst its ectopic expression in basal-like breast cancer
cells partly rescues the epithelial, differentiated and pacli-
taxel-sensitive phenotype. Gene expression profiling iden-
tifies down-stream EP300 targets associated with drug
resistance, EMT and CSCs. Finally, immunohistochemical
analysis reveals a strong downregulation of EP300 in
metaplastic breast cancer, a rare, but aggressive form of
invasive breast cancer with histological evidence of EMT,
which has a poor clinical outcome.
Materials and methods
Cells
MCF-7 and MDA-MB-231 cells were obtained from
Sigma-Aldrich, CAL51 cells from the German Resource
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Centre for Biological Material (DSMZ), HCT116 and
HCT-KOEP300 (a genetic EP300 knockout from HCT116
cells [11]) cells from Cancer Research Technology and
HEK293T cells from the American Type Culture Collec-
tion. Minimally transformed human mammary epithelial
cells (MTMEC) were a gift from William Hahn (Dana
Farber, Boston). MTMECs express TERT, SV40 large T
antigen, a constitutively active form of PI3K, p110a and
oncogenic ras [16] and were maintained in serum-free
HuMEC medium (Life Technologies). HEK293T were
maintained in DMEM supplemented with 4.5 g/L glucose,
10% foetal calf serum and 4 mM L-glutamine (Life Tech-
nologies). MCF-7 and MDA-MB-231 cells were main-
tained as HEK293T cells but with 1 g/L glucose. HCT116
cells were maintained in McCoy’s 5A medium supple-
mented with 10% foetal calf serum and 4 mM L-glutamine.
Downregulation of EP300 was obtained by stable ex-
pression of hairpins in the lentiviral vector pGIPZ
(Thermo Scientific). Two different hairpins,
V3LHS_331296 (mature antisense: TGTGCACAAC
TGTTTGCCG) and V3LHS_331295 (mature antisense:
TAATCTATCTTCAGTAGCT), from the RNAi Consor-
tium (Broad Institute) were used. Viral transductions were
essentially as described [18] and cells were selected and
maintained with 1 lg/mL puromycin. Overexpression of
EP300 was obtained by stable expression of a pcDNA3.1-
derived construct carrying the full-length EP300 cDNA
(Addgene #23252) [19]. Cells were transfected with GenJet
(SignaGen Laboratories) following manufacturer’s instruc-
tions and selected and maintained with 1 mg/mL G418.
Pools of at least 200 G418-resistant clones were used in all
cases. Paclitaxel-resistant lines were generated following a
‘‘pulse’’ methodology as described [12]. In short, cells were
treated with paclitaxel (20 nM for MCF7-shEP300, 15 nM
for MTMEC-shEP300 and 40 nM for HCT-KOEP300
derivatives) for 3 days, after which the cells were grown
drug-free for two passages before repeating the drug treat-
ment. Resistant lines were obtained after several months and
did not show any significant cell death after drug treatment.
Gene expression analysis
Total RNA (isolated using a RNeasy kit, Qiagen) was
reverse transcribed with MuLV reverse transcriptase
(High-Capacity RNA-to-cDNA kit, Applied Biosystems)
and real-time quantitative PCR (QPCR) was performed
using SYBR Green (Applied Biosystems) on an ABI Prism
7700 detection system (PerkinElmer Life Sciences). RPS14
and RPLP0 mRNAs were used as normalizers. A com-
parative threshold cycle was used to determine the relative
gene expression as previously described [20]. Oligonu-
cleotides used for gene expression analysis are shown in
Supplementary Table 1.
Antibodies
Antibodies for immunodetection following standard
immunoblotting procedures were 24E10 for E-cadherin
(Cell Signalling Technology), ab10485 for EP300 (Ab-
cam), AC-15 (ab6276; Abcam) for b-actin and Bcl-2 (100)
[sc-509] and C-5 (sc-365962) for Lamin B1 (Santa Cruz
Biotechnology). Membranes were incubated with anti-
rabbit (926-32213, IRDye 800CW Donkey anti-Rabbit,
LI-COR) and anti-mouse (926-68072, IRDye 680RD
Donkey anti-Mouse, LI-COR) secondary antibodies and
the bands were visualised and quantified using an Odyssey
Infrared Imaging System (LI-COR Biotechnology-UK
Ltd).
Drug sensitivity assay
The drug concentration necessary to kill 50% of cells
(IC50) after 3 days of culture (6-well dishes; 3000 cells/
well) was obtained after sulphorhodamine B (Sigma-
Aldrich) staining [21] as previously described [22].
Drug resistance clonogenic assay
Cells (2 9 105) were seeded, at least in triplicate, in 25
cm2 culture flasks and exposed to a single dose of pacli-
taxel (Tocris Bioscience) for 3 days. Cells were kept in
culture for 21 days with drug-free medium changes every
three days. Drug-resistant clones were fixed with 4%
paraformaldehyde and stained with 0.2% crystal violet and
counted.
Anchorage-independent growth assays
To assess the capacity of CSCs to propagate in an
anchorage-independent manner, both soft agar and sphere
assays were performed. Cells (5 9 104) were seeded in
0.3% agar noble in complete DMEM medium on 30 mm
plates with a bottom layer of solidified 0.6% agar noble in
the same medium. Triplicate cultures for each cell type
were maintained for 4 weeks at 37 C in an atmosphere of
5% CO2 and 95% air, with 200 lL fresh medium added
once a week. Colonies larger than 50 lm in diameter were
counted after 4 weeks and stained with crystal violet. For
the sphere formation assay [23], cells (100–200) were
plated in each well of an ultralow attachment 24-well plate
(Corning) with 3 mL serum-free mammary epithelial
growth medium (MEGM, BioWhittaker), supplemented
with 2% B27 supplement, 20 ng/mL epidermal growth
factor and 20 ng/mL fibroblast growth factor-basic (all
from Invitrogen). Cells were grown for 14 days, replen-
ishing 500 lL of medium every 3–5 days, until spherical
clusters larger than 50 lm diameter were counted.
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Flow cytometry
For stem cell markers, CD44 (G44-26, APC) and CD24
(ML5, PE), both from BD Biosciences, were used essen-
tially as described [23]. An Aldefluor assay kit (StemCell
Technologies) was used for the determination of aldehyde
dehydrogenase (ALDH) activity by flow cytometry essen-
tially as described [23]. Briefly, cells were resuspended in
assay buffer (106 cells/mL). Activated Aldefluor substrate
(5 lL) was added to samples and incubated at 37 C for
45 min to allow substrate conversion. A sample with the
ALDH inhibitor diethylaminobenzaldehyde was used as a
negative control.
Microarray hybridization, processing and data
analysis
Total RNA was prepared from three independent biological
replicates of each cell line using a RNeasy Kit (Qiagen).
RNA integrity was evaluated using an Agilent 2100 Bioan-
alyzer. cDNA synthesis and further processing was per-
formed using GeneChip WT PLUS Reagent kit
(Affymetrix). Hybridization to Affymetrix GeneChip
Human Gene ST Arrays followed manufacturer’s protocol.
The control probes used to measure microarray hybridization
efficiency were obtained from the Affymetrix online data-
base and were filtered out before analysis. Raw signal
intensity, background correction, quantile normalization,
log2 transformation and probeset summarization were per-
formed with Affymetrix Expression Console Software.
Differential gene expression was analysed using Partek
Genomic Suite (Partek, USA). The microarray data were
deposited with the NCBI Gene Expression Omnibus (http://
ncbi.nlm.nih.gov/geo/) under accession number GSE76200.
Immunohistochemistry
A total of 17 FFPE metaplastic breast cancer samples and
17 normal (reduction mammoplasty/benign) breast tissue
samples were used. Samples were collected from the
Imperial College Healthcare Tissue Bank (R14086) and
Breast Cancer Now Tissue Bank (BCNTB-TR000054)
after ethics approval by both institutions. Immunohisto-
chemical staining was performed using antibodies against
EP300 (HPA003128, Sigma-Aldrich, dilution 1:200) and
E-cadherin (Clone 36, #610181, BD Biosciences, dilution
1:200). EP300 antibody specificity was validated with a
synthetic peptide (APrEST73567, Atlas Antibodies) com-
petition assay following manufacturer’s protocol. A stan-
dard operating procedure for immunohistochemical
staining (Charing Cross Hospital Histopathology Labora-
tory, Q-Pulse index Code: CEL-LP-172-X, Ver. 1.6, 2013,
Supplementary Table 2) modified to use the Bond Polymer
Refine Detection Kit (DS9800, Leica Biosystems) was
used. All sections were visualised with diaminobenzidine
and counterstained with haematoxylin. EP300 and E-cad-
herin immunoreactivity was scored based on staining
intensity ranging from 0 to ?3: 0 = null, ?1 = low,
?2 = intermediate and ?3 = high, as described [24].
More than six representative fields of each slide were
analysed for determining EP300 and E-cadherin expression
levels. The percentage of EP300- or E-cadherin-positive
tumour cells scored as high (?2 or ?3 in at least 66% of
cells) or low/none was calculated for each slide by two
investigators (MA and EY) and validated by a pathologist
(SS) and clinical oncologist (RCC).
Statistical analysis
Statistical evaluations were performed by Student’s t test
for paired data or one-way ANOVA with Dunnett’s mul-
tiple comparison test. Data were considered significant at a
P-value inferior to 0.05.
Results
Modulation of EP300 in cell model systems
In order to study how breast cancer epithelial cells respond
to EP300 downregulation, we generated stably transfected
MCF-7 cells with a lentivirus driving the expression of
hairpins targeting EP300 mRNA. EP300 expression was
high in this luminal cell line, but decreased to a high extent
after the expression of two different EP300 hairpins. As
expected, downregulation of EP300 led to a dramatic
downregulation of E-cadherin (Fig. 1a).
HCT116 colon carcinoma cells are hemizygous for
EP300 and due to the high frequency of homologous
recombination in these cells, an EP300 genetic knocked-
out model showing characteristics of EMT, has previously
been generated [11]. These cells show, as expected, a lack
of both EP300 and E-cadherin (Fig. 1a) and thus represent
also a good cell system to study the phenotypic effects in
an EP300-null background.
Triple-negative, basal-like breast cancer cells show
many mesenchymal characteristics and thus we generated
stably transfected cells derived from CAL51 and MDA-
MB-231 in which EP300 was upregulated after transfection
with an expression vector. Both CAL51 and MDA-MB-231
cells expressed low to moderate levels of EP300 that were
upregulated in the stably overexpressed lines. As expected,
E-cadherin was not detectable in the control cells, but its
expression was upregulated in both CAL-EP300 and
MDA-EP300 cells, although at a higher extent in the for-
mer than the latter (Fig. 1b).
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Modulation of EP300 expression alters paclitaxel
sensitivity and the generation of paclitaxel-resistant
cells
Paclitaxel is used both in the primary setting to reduce the
risk of recurrence and in the advanced stage after lack of
response to anthracyclines. We have previously shown that
in a minimally transformed cellular model of breast cancer,
experimental downregulation of EP300 decreases pacli-
taxel sensitivity and leads to the generation of paclitaxel-
resistant cells [17]. In order to ascertain the generalized
effect on paclitaxel response, we determined its IC50 values
in the cell models generated above. EP300 downregulation
led to an increase in the IC50 in MCF-7 cells, giving
between a 3.8- and 5.7-fold increase in resistance
depending on the hairpin used (Table 1). Importantly, this
Fig. 1 Experimental modulation of EP300 in cellular models.
Expression of EP300 and E-cadherin was determined by immunoblot
analyses. a EP300 was downregulated in breast cancer luminal MCF-
7 cells by lentiviral expression of two different EP300 hairpins
(MCF7-shEP300-1 and MCF7-shEP300-2). Cells expressing the
empty pGIPZ vector (MCF7-shev) were used as control. b, a genetic
knock-out of EP300 (HCT-KOEP300) is available in colon carcinoma
HCT116 cells. This cell line is hemizygous for the EP300 locus and
generates a C-terminus truncated EP300 protein [10]—note its lower
molecular mass (tEP300, truncated EP300). Paclitaxel-resistant
derivatives are indicated with the -TX name extension. c, d EP300
was upregulated in breast cancer basal-like CAL51 and MDA-MB-
231 cells with an EP300 expression cassette in pcDNA3.1 (CAL-
EP300 and MDA-EP300). In both cases, cells transfected with
pcDNA3.1 were used as controls (CAL-ev and MDA-ev). Lamin B
was used as a loading control. Representative pictures of three
replicates are shown. Immunoblots were quantified and data are
shown in the histograms as average ± SD of three blots. All
statistical comparisons (*P\ 0.05) versus control cells
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increase in paclitaxel resistance was also reproduced in
EP300-knocked-out colon carcinoma HCT116 cells with
an IC50 increase of 4.6-fold (Table 1). Conversely, when
EP300 was experimentally upregulated in CAL51 and
MDA-MB-231 cells, an increase in paclitaxel sensitivity
(2.3- and 3.5-fold, respectively) was observed (Table 1).
Modulation of EP300 did not only affect short-term drug
sensitivity, but also the long-term generation of drug-re-
sistant cells. After 3 weeks of culture, and following an
initial single paclitaxel treatment during 3 days, the num-
ber of drug-resistant clones increased approximately five-
fold in MCF7-shEP300 (Fig. 2a) and 15-fold in HCT-
KOEP300 cells (Fig. 2b). Conversely, overexpression of
EP300 led to a reduction in the number of resistant clones
by approximately three-fold in CAL-EP300 cells (Fig. 2c).
When pools of resistant clones were isolated (MCF7-
shEP300-1-TX, MCF7-shEP300-2-TX and HCT-
KOEP300-TX), their paclitaxel IC50 values indicated a
further decrease in drug sensitivity (Table 1). Thus, mod-
ulation of EP300 alters paclitaxel resistance.
Modulation of EP300 expression alters cancer stem
cell markers and anchorage independence
Drug resistance is strongly associated with CSC charac-
teristics, such as a CD44?/CD24-/ALDH1? phenotype,
and the ability to survive and grow in an anchorage-inde-
pendent manner [25, 26]. We asked, first, whether modu-
lation of EP300 would alter the proportion of CSCs. For
this, we performed a double stain with CD44 and CD24
antibodies and determined the percentage of cells positive
for each marker. As expected, MCF7-ev control cells
showed a low proportion of CD44?/CD24- cells (*1%).
However, there was an increase in both MCF7-shEP300 (to
2.5–3%) as well as in their paclitaxel-resistant derivatives
(to 5–6%; Fig. 3a). The increase in the CD44?/CD24-
population upon downregulation of EP300 was further
confirmed using HCT116 cells. Although these cells have a
high proportion of CD44?/CD24- cells, EP300 knock-
Table 1 Modulation of
paclitaxel sensitivity after
experimental modulation of
EP300 expression in cell models
Cell type Cell derivative EP300 status IC50 (nM)
a Fold resistance Fold sensitivity
MCF7 MCF7-shev 1.3
MCF7-shEP300-1 Downregulated 5.0 3.8
MCF7-shEP300-2 Downregulated 7.5 5.7
MCF7-shEP300-1-TX Downregulated 45.6 35.1
MCF7-shEP300-2-TX Downregulated 29.6 22.7
HCT116 HCT116 3.1
HCT-KOEP300 Knockedout 14.2 4.6
HCT-KOEP300-TX Knockedout 53.0 17.1
CAL51 CAL-ev 4.2
CAL-EP300 Upregulated 1.8 2.3
MDA-MB-231 MDA-ev 32.1
MDA-EP300 Upregulated 9.2 3.5
a Paclitaxel concentration at which proliferation after 3 days was reduced by 50% estimated from the
corresponding dose–response curves
Fig. 2 EP300 regulates the generation of paclitaxel resistance. Cells
were treated for 3 days with paclitaxel and drug-resistant clones were
stained with crystal violet 3 weeks after (left panels) and counted
(right panels). a, MCF-7 cells. b, HCT116 cells. c, CAL51 cells.
Numerical data represent the average ± SD of three independent
experiments. All statistical comparisons (*P\ 0.05) versus control
cells. Pictorial data show a representative of three different
experiments
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down led to a further increase in this subpopulation,
from *33% in HCT116 cells to *44% in HCT-KOEP300
cells, that increased further to *65% in HCT-KOEP300-
TX-resistant cells (Fig. 3b). Conversely, experimental
upregulation of EP300 expression led to a decrease in the
CD44?/CD24- subpopulation of MDA-MB-231 cells,
from *9% in MDA-ev to *3% in MDA-EP300 cells
(Fig. 3c). Despite its triple-negative and basal characteris-
tics, CAL51 cells have a very low CD44 expression [27].
However, determination of ALDH? cells by flow cytom-
etry confirmed that experimental upregulation of EP300 led
to a decrease in the percentage of ALDH? CAL51 cells
(from *43% in CAL-ev to *23% in CAL-EP300;
Fig. 3d). Thus, there is an inverse relationship between
EP300 expression and CSC markers.
In order to assess the functionality of the stem cell
markers above, two complementary anchorage indepen-
dence assays were performed, sphere formation in liquid
cultures using low attachment plates and colony
formation in soft agar. Downregulation of EP300 in
MCF-7 cells led to an increase in both the number of
mammospheres (*7-fold) and colonies in soft agar (*2-
fold). Paclitaxel-resistant derivatives showed a further
two-fold increase in the number of mammospheres,
although this was not observed in the formation of
colonies in soft agar (Fig. 4a, d). These results were
confirmed in HCT116 cells. Thus, the number of mam-
mospheres increased two-fold and 3.5-fold in HCT-
KOEP300 and HCT-KOEP300-TX cells, respectively,
whereas the number of colonies in soft agar increased by
two-fold and 2.5-fold in the same cells (Fig. 4b, e).
Conversely, CAL51 cells overexpressing EP300 showed
a 50% reduction in the anchorage-independent growth
efficiency (Fig. 4c, f). MDA-MB-231, which is a cell
line notoriously recalcitrant for these types of assay [28],
did not generate robust tumor spheres.
Overall, these results indicate a negative regulation of
CSC characteristics by EP300.
Fig. 3 EP300 regulates stem cell markers. a–c Flow cytometry plots
after staining (a MCF-7 cells; b HCT116 cells; c MDA-MB-231 cells)
with CD44-APC- and CD24-PE-conjugated antibodies. Paclitaxel-
resistant cell derivatives (MCF7-shEP300-1-TX, MCF7-shEP300-2-
TX and HCT-KOEP300) were generated from the corresponding cells
after selection with 20 nM (MCF-7 cells) and 40 nM paclitaxel
(HCT116 cells). Histograms indicate the percentage of CD44?/
CD24- cells. d Upregulation of EP300 in CAL51 cells reduces the
percentage of ALDH? cells. Cells were treated with Aldefluor alone
(ALDH) or in the presence of the ALDH inhibitor diethylaminoben-
zaldehyde (Control) and then analysed by flow cytometry. The green
gate was set up with the control cells to include no more than 1% of
the population and was used to determine the percentage of ALDH-
positive cells in the absence of inhibitor. Representative flow
cytometry plots are shown. Numerical data represent the aver-
age ± SD of three independent experiments. All statistical compar-
isons (*P\ 0.05) versus control cells
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Genome-wide expression analysis indicates EP300
has a role in regulating adhesion, apoptosis
and stemness
In order to gain insights into the down-stream molecules
regulated by EP300, and potential effectors of the pheno-
types described above, a genome-wide expression profile
analysis was performed in MCF7-shEP300 cells and their
paclitaxel-resistant derivatives (Fig. 5a). As expected for a
chromatin modifier and regulator of transcription, more
than 4000 genes were differentially regulated upon EP300
downregulation and in paclitaxel-resistant derivatives
(Fig. 5b). In order to validate the array data, in addition to
EP300, the expression of another 10 genes was determined
by QPCR. Expression of both up- and downregulated genes
was highly reproducible between the two platforms
(Fig. 5c), giving a high degree of confidence for the
obtained gene expression profiles. The most differentially
regulated genes are shown in Supplementary Table 3.
Importantly, expression of key molecules in the MCF-7
signature, such as CEACAM5 (adhesion), CAPN9 (cy-
toskeletal remodelling), ABCG2 (stemness), BCL2 and
TNFRSF11B (apoptosis), ITAG2 and ITAG3 (migration)
and TGFB2 (metastasis), among others, was reproduced in
MTMEC-shEP300 cells (Fig. 6a). Moreover, upregulation
of BCL2 and ABCG2 was also demonstrated in both HCT-
KOEP300 cells and its paclitaxel-resistant derivative
(Fig. 6b, c), indicating that regulation of these two
important molecules involved in apoptosis response/drug
resistance and stemness is not breast cancer specific and
probably represents major EP300-regulated pathways.
EP300 is downregulated in metaplastic breast
cancer
Metaplastic breast cancer is a rare (less than 1% of invasive
breast cancers) and histologically diverse subtype of breast
carcinoma with very poor prognosis. It shows the charac-
teristics of cells undergoing EMT (spindle morphology,
reprogramming of epithelial–mesenchymal markers), with
acquisition of CSCs markers (CD44?) and is more resistant
to chemotherapy than basal-like or luminal cancers
[29, 30]. As EP300 regulates most of the characteristics
associated with these phenotypes, we asked whether EP300
Fig. 4 EP300 regulates anchorage independence. Anchorage inde-
pendence was determined by mammosphere formation in low
attachment plates (a–c) and the formation of clones in soft agar (d–
e) after 2 and 4 weeks, respectively. Representative pictures of at
least three independent experiments are shown. Numerical data
indicate the anchorage independence efficiency after counting tumour
spheres larger than 50 lm in diameter and is represented as the
average ± SD of three independent experiments. All statistical
comparisons (*P\ 0.05) versus control cells
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would be downregulated in metaplastic breast cancer. In
order to detect EP300 by immunohistochemistry, we first
validated a commercial antibody used for the Human
Protein Atlas [31] by peptide competition (Fig. 7a). EP300
expression in normal/benign breast tissue was high in both
the epithelial and stroma compartments. However, epithe-
lial cells showed both nuclear and cytoplasmic staining,
whereas cells from the stroma showed exclusively nuclear
staining. As expected, E-cadherin expression was strong in
the epithelial component and absent in the stroma
(Fig. 7b). We analysed 17 metaplastic breast cancer sam-
ples that all scored negative or low for E-cadherin
expression (scores 0 or 1) and found that all of them also
scored low (score 1) for EP300 expression in the mes-
enchymal metaplastic component (Fig. 7b). Importantly,
most of the EP300 nuclear staining was lost in metaplastic
samples, their low positivity being the result of cytoplasmic
expression (Fig. 7c). Eight (47%) metaplastic breast can-
cers were histologically heterogeneous, mainly with the
nests of squamous differentiation showing positivity for
Fig. 5 Genome-wide expression profile of EP300-downregulated
MCF-7 cells, and their paclitaxel-resistant derivatives. a Hierarchical
clustering of differentially expressed genes. Differentially upregu-
lated expression values are shown in red, downregulated in green.
Scale represents colour values corresponding to lg2 expression. b,
Venn diagram indicating the number of differentially expressed genes
in each of the pair-wise comparisons to MCF7-shev control cells.
There were 4044 common differentially expressed genes present in all
cells after downregulation of EP300. c Eleven genes were selected for
validation by quantitative PCR. The top panel for each gene shows
the normalized fluorescence from Affymetrix array expression data.
The lower panel for each gene indicates the normalized QPCR data
relative to the expression data obtained in control MCF7-shev cells.
QPCR data represent the mean ± SD from three replicates
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both E-cadherin and EP300 (Fig. 7d). Due to the rarity of
this type of breast cancer and the small sample size, no
associations with other clinical parameters were sought.
Thus, EP300 is downregulated in metaplastic breast cancer.
Discussion
We have recently described a novel pathway controlling
drug resistance in breast cancer cells. Upstream of the
pathway, three miRs (miR-106b, miR-93 and miR-25)
transcribed from the same cluster, target EP300, a tran-
scriptional activator of E-cadherin. Upregulation of these
miRs, found in aggressive basal-like, oestrogen receptor-
negative, grade 3 breast cancers [13] and drug-resistant cell
models, leads to a downregulation of EP300 and E-cad-
herin with initiation of an EMT [12]. However, miRs
regulate the expression of many genes, and the contribution
to EMT by miR targets other than EP300 cannot be ruled
out. Here we describe that experimental modulation of
EP300 in breast and colon cancer cell models alters
paclitaxel sensitivity and the generation of resistant cells.
Importantly, EP300 is also associated with stemness. Its
downregulation is associated with increased in vitro
tumorigenicity and cancer stem cell-like markers, whilst its
ectopic expression in basal breast cancer cells partly res-
cues the epithelial, differentiated, paclitaxel-sensitive
phenotype. Transcriptome analysis identifies key mole-
cules associated with these phenotypes such as CEACAM5
(adhesion), CAPN9 (cytoskeletal remodelling), ABCG2
(stemness), BCL2 (apoptosis), ITAG2 and ITAG3 (migra-
tion) and TGFB2 (metastasis). Lastly, we have unveiled
that EP300 is downregulated in metaplastic breast cancer, a
rare aggressive form of the disease with histological evi-
dence of EMT and poor clinical outcome.
During the initiation of the metastatic cascade, cells
undergo reprogramming to a less differentiated, therapy-
resistant and morphologically changed phenotype [32]. As
EP300 functions as a histone acetyltransferase [7], with the
potential to modulate the expression of a plethora of genes,
it is not surprising that its experimental downregulation in
MCF-7 cells alters the expression of more than 4000 genes.
Although the main function of EP300 as a transcriptional
activator is well-established, such as in the case of CDH1
(E-cadherin) transactivation [5], it may also lead to gene
repression [33, 34]. Early work on MCF-7 cells expressing
ribozymes specific for EP300 indicates that DNA damage-
induced apoptosis is impaired in EP300-deficient cells [35].
In bladder cancer cells, experimental downregulation of
EP300 leads to doxorubicin and cisplatin resistance
Fig. 6 Validation of the EP300 signature in other cell models.
a QPCR data from EP-downregulated minimally transformed mam-
mary epithelial cells, and their paclitaxel-resistant derivatives. The
gene set is the same that is used in Fig. 5c to validate the MCF-7
signature. b QPCR data of anti-apoptotic BCL2 and stem cell marker
ABCG2 from the MCF-7 signature in HCT116 cells. c and d, Bcl-2
immunoblot (top panels) and blot quantification (lower panels) in
both MCF-7 (c) and HCT116 (d) cell derivatives. b-actin is used as a
loading control. Numerical data represent the average ± SD of three
independent experiments. All statistical comparisons (*P\ 0.05)
versus control cells. Immunoblot shows a representative of three
independent experiments
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[14, 15] and, using a minimally transformed model of
mammary epithelial cells in which EP300 has been
downregulated, we have recently found an impaired cas-
pase-9 and caspase 3/7 activation following paclitaxel
treatment [17]. EP300-deficient cells show multidrug
resistance to a variety of structurally and functionally dif-
ferent drugs and c-radiation, a phenotype that is ABC
transporter independent [12, 17]. The EP300 signature
presented here highlights the importance of BCL-2 in the
apoptotic evasion reported in EP300-deficient cells.
Although a definitive mechanistic insight in the regulation
of apoptosis by EP300 has not yet been established, EP300
has been described to be associated with SATB1, leading to
the repression of CYBB, the key component of the phago-
cyte NADPH oxidase [36]. SATB1 has also been described
to bind the BCL-2 promoter where it has a negative tran-
scriptional regulatory function [37]. Other EP300-
associated factor, PCAF, accelerates apoptosis by repress-
ing a GLI/BCL2/BAX axis in hepatocellular carcinoma
[38]. It is thus tempting to speculate that these mechanisms
may also play a role in breast cancer cells.
EP300-deficient cells increase their motility and inva-
sive properties, both in colon and breast cancer cells [11],
[12]. This phenotype involves major cellular reprogram-
ming highlighted in the EP300 signature described here
with downregulation of cell adhesion molecules, such as
EPCAM5 and EPCAM6, and upregulation of collagens
(COL12A1 and COL4A5) and mesenchymal OB-cadherin
(CDH11), a characteristic EMT marker [39]. Upregulation
of fibulins (EFEMP1 and HMCN1), which bind EGFR and
regulate cell adhesion and migration, correlates with
tumour progression and poor prognosis in ovarian cancer
[40]. Upregulation of EPHA4, a receptor tyrosine kinase
which binds ephrin family ligands, modulates cell
Fig. 7 EP300 is downregulated in metaplastic breast cancer. a Val-
idation of EP300 antibody using 10- and 100-fold molar excess
competing peptide in two independent breast cancer samples. H&E,
haematoxylin and eosin staining. Scale bar, 200 lm. b EP300 and
E-cadherin staining in three representative samples of normal breast
and metaplastic breast cancer. H&E, haematoxylin and eosin staining.
Scale bar, 200 lm. c Loss of EP300 nuclear staining in metaplastic
breast cancer. Pictures show representative zoomed-in shots
illustrating nuclear EP300 localization in normal breast and its loss
in metaplastic breast cancer. Scale bar, 20 lm. d Representative
EP300 and E-cadherin staining in a metaplastic breast cancer sample
with a squamous epithelium nest (bottom half). The top half is
composed of spindle-like cells. Note the absence of E-cadherin and
EP300 expression in the mesenchymal component but positive
staining in the squamous nest. Scale bar, 200 lm
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morphology and promotes migration in glioma cells [41].
Consistently, high levels of EPHA4 correlate with a
reduced overall survival in breast cancer patients [42].
Downregulation of ARHGAP20, a GTPase activator of
Rho-type GTPases, favours Rho to be in the active GTP-
bound state and promotes motility [43]. Reorganization of
the actin cytoskeleton is also important for cellular
remodelling, with the downregulation of plastin (PLS3)
and other actin-binding proteins (CNN2), as well as
upregulation of WIPF1, which intervenes in the disas-
sembly of stress fibres in favour of filopodia formation.
Importantly, high expression of WIPF1 is associated with
poor prognosis in breast cancer [44]. Cytoskeletal remod-
elling is also regulated by CAPN9, a member of the calpain
family. Low CAPN9 expression has been associated with
poorer clinical outcome in breast cancer patients following
endocrine therapy [45].
TGFB2 is one of the three highly homologous isoforms
of TGF-b found in humans. TGF-b is a potent inducer of
EMT in mammary cells, the acquisition of CSC properties
and chemotherapy resistance [46, 47]. TGF-b also induces
FGFR switching, causing murine mammary epithelial cells
to become sensitive to FGF2 [48]. A similar effect is
observed in the EP300 signature, with upregulation of
TGFB2 and FGFR2. Importantly, FGF2 induces mes-
enchymal OB-cadherin (CDH11) expression [49], also
observed in EP300-deficient MCF-7 cells. Importantly,
metaplastic breast cancer is enriched in the markers of
CSCs and EMT [50] and we show here low EP300
expression when compared to non-cancerous breast
epithelium. Transcriptome profiling of metaplastic breast
cancer indicates downregulation of epithelial phenotypes,
remodelling of the extracellular matrix and EMT [51, 52].
Of note that the small sample analysed by Lien et al.
indicates a concordance with differentially regulated genes
in the MCF-7 EP300 signature, downregulation of CDH1,
CEACAM6 and ARHGAP8, another Rho GTPase-activat-
ing protein, as well as upregulation of BCL2A1, EFNB1
(ephrin B1) and osteoprotegerin (TNFRSF11B), a soluble
TRAIL decoy receptor secreted by inflammatory and
invasive breast cancer cells that induces aneuploidy, cell
proliferation and angiogenesis [53].
In conclusion, we demonstrate that tumour suppressor
EP300 is poorly expressed in metaplastic breast cancer and
is a master regulator of EMT, CSCs and drug resistance.
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